Please ensure Javascript is enabled for purposes of website accessibility
Patrick Bafuma

Patrick Bafuma


Recent articles

buy sell hold die money Getty

3 Things Nano-X Needs to Do to Make You Rich

The FDA recently cleared its digital X-ray concept; here's what has to happen next to generate shareholder value.

woman sits in front of laptop at desk

Better Healthcare Stock for the Next 10 Years: Butterfly Network vs. Shockwave Medical

Which of these amazing medical technology companies is better for your portfolio for the next decade?

GettyImages-1186545957 (1)

Does 2021's Best Biopharma to Work for Belong in Your Portfolio?

Horizon Therapeutics has a clear path to significant sales growth.

male and female doctor meet in an office

This Medical Equipment Company's Recent Earnings Gave Investors Butterflies

Butterfly Network's debut earnings call last week was impressive, but might have spooked some investors.

female doctor reviews scans at her desk

3 Cancer Diagnostic Monster Stocks on Sale

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

spring green shoots flowers blooming march month getty

This Pharma Can Breathe New Life Into Your Portfolio

Will future Tyvaso revenue growth push United Therapeutics to new heights?

a baseball in a glove and a baseball bat lying on grass

This 2020 Biotech IPO Is Poised to Break Out in 2021

Revolution Medicines' leading compound is shaping up to be a platform in a pill.

health visitor evaluates heartbeat of senior man

Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath

Which healthcare company is a better play for the next decade?

happy traders wall street celebrating profit growth win

This Big Leap in Cancer Treatment Could Change the Landscape

TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.

hand drawing chart stock return

2,500% Returns? This Stock Is Like Buying Illumina in 2007

10x Genomics is powering the next generation of biotech research.


3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass

Can this brain health-focused biotech continue to rise, or will it fade -- again?

GettyImages-909176662 (1)

Why bluebird bio Is Worth a Look Today

It's good news for investors as this biotech brings impressive results to the rare disease market.

young couple worried looking at bill expense finance POC

3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy

Can this pharma blow past its highs from 10 years ago, or will it fade away -- again?

trader stock investing chart graph online buy sell hold

This Underperforming Biotech Is Ready to Beat the Market

Incyte is betting bigger on ruxolitinib to bring back growth.

healthcare worker hospital nurse doctor fluid infusion

Beyond COVID, Regeneron Is Betting Big on Oncology

Future growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda.

senior man and woman smiling and toasting with glasses of white wine couple happy celebrating party

Get an Earful of This Growing Healthcare Stock

Eargo is looking to modernize the hearing aid market, and we're all ears.


Like Guardant Health? You'll Love CareDx

This under-the-radar diagnostics company is thriving yet reasonably priced.


Magenta Is Ready to Paint Your Portfolio Green

This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.


Why Turning Point Is Turning Heads

This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?


It's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting Started

Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.